515 related articles for article (PubMed ID: 10601379)
1. Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue.
Galipeau PC; Prevo LJ; Sanchez CA; Longton GM; Reid BJ
J Natl Cancer Inst; 1999 Dec; 91(24):2087-95. PubMed ID: 10601379
[TBL] [Abstract][Full Text] [Related]
2. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression.
Reid BJ; Prevo LJ; Galipeau PC; Sanchez CA; Longton G; Levine DS; Blount PL; Rabinovitch PS
Am J Gastroenterol; 2001 Oct; 96(10):2839-48. PubMed ID: 11693316
[TBL] [Abstract][Full Text] [Related]
3. Losses of heterozygosity on chromosomes 9p and 17p are frequent events in Barrett's metaplasia not associated with dysplasia or adenocarcinoma.
Suspiro A; Pereira AD; Afonso A; Albuquerque C; Chaves P; Soares J; Leitão CN
Am J Gastroenterol; 2003 Apr; 98(4):728-34. PubMed ID: 12738448
[TBL] [Abstract][Full Text] [Related]
4. Crypt dysplasia with surface maturation: a clinical, pathologic, and molecular study of a Barrett's esophagus cohort.
Lomo LC; Blount PL; Sanchez CA; Li X; Galipeau PC; Cowan DS; Ayub K; Rabinovitch PS; Reid BJ; Odze RD
Am J Surg Pathol; 2006 Apr; 30(4):423-35. PubMed ID: 16625087
[TBL] [Abstract][Full Text] [Related]
5. 3p21, 5q21, 9p21 and 17p13.1 allelic deletions are potential markers of individuals with a high risk of developing adenocarcinoma in Barrett's epithelium without dysplasia.
Sanz-Ortega J; Hernández S; Saez MC; Sierra E; Sanz-Ortega G; Torres A; Balibrea JL; Sanz-Esponera J; Merino MJ
Hepatogastroenterology; 2003; 50(50):404-7. PubMed ID: 12749233
[TBL] [Abstract][Full Text] [Related]
6. Re: clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue.
Walch A; Mueller J; Höfler H; Werner M
J Natl Cancer Inst; 2000 Jul; 92(14):1182-3. PubMed ID: 10904093
[No Abstract] [Full Text] [Related]
7. Serum selenium levels in relation to markers of neoplastic progression among persons with Barrett's esophagus.
Rudolph RE; Vaughan TL; Kristal AR; Blount PL; Levine DS; Galipeau PC; Prevo LJ; Sanchez CA; Rabinovitch PS; Reid BJ
J Natl Cancer Inst; 2003 May; 95(10):750-7. PubMed ID: 12759393
[TBL] [Abstract][Full Text] [Related]
8. Mutagen sensitivity and neoplastic progression in patients with Barrett's esophagus: a prospective analysis.
Chao DL; Maley CC; Wu X; Farrow DC; Galipeau PC; Sanchez CA; Paulson TG; Rabinovitch PS; Reid BJ; Spitz MR; Vaughan TL
Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1935-40. PubMed ID: 17035402
[TBL] [Abstract][Full Text] [Related]
9. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma.
Galipeau PC; Li X; Blount PL; Maley CC; Sanchez CA; Odze RD; Ayub K; Rabinovitch PS; Vaughan TL; Reid BJ
PLoS Med; 2007 Feb; 4(2):e67. PubMed ID: 17326708
[TBL] [Abstract][Full Text] [Related]
10. p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium.
Wong DJ; Paulson TG; Prevo LJ; Galipeau PC; Longton G; Blount PL; Reid BJ
Cancer Res; 2001 Nov; 61(22):8284-9. PubMed ID: 11719461
[TBL] [Abstract][Full Text] [Related]
11. Loss of heterozygosity on chromosome 17p predicts neoplastic progression in Barrett's esophagus.
Dolan K; Morris AI; Gosney JR; Field JK; Sutton R
J Gastroenterol Hepatol; 2003 Jun; 18(6):683-9. PubMed ID: 12753151
[TBL] [Abstract][Full Text] [Related]
12. Nonsteroidal anti-inflammatory drug use, body mass index, and anthropometry in relation to genetic and flow cytometric abnormalities in Barrett's esophagus.
Vaughan TL; Kristal AR; Blount PL; Levine DS; Galipeau PC; Prevo LJ; Sanchez CA; Rabinovitch PS; Reid BJ
Cancer Epidemiol Biomarkers Prev; 2002 Aug; 11(8):745-52. PubMed ID: 12163328
[TBL] [Abstract][Full Text] [Related]
13. Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus.
Barrett MT; Sanchez CA; Galipeau PC; Neshat K; Emond M; Reid BJ
Oncogene; 1996 Nov; 13(9):1867-73. PubMed ID: 8934532
[TBL] [Abstract][Full Text] [Related]
14. LOH at the sites of the DCC, APC, and TP53 tumor suppressor genes occurs in Barrett's metaplasia and dysplasia adjacent to adenocarcinoma of the esophagus.
Dolan K; Garde J; Walker SJ; Sutton R; Gosney J; Field JK
Hum Pathol; 1999 Dec; 30(12):1508-14. PubMed ID: 10667431
[TBL] [Abstract][Full Text] [Related]
15. Molecular genetic analysis of surveillance biopsy samples from Barrett's mucosa--significance of sampling.
Werther M; Saure C; Pahl R; Schorr F; Rüschoff J; Alles JU; Heinmöller E
Pathol Res Pract; 2008; 204(5):285-94. PubMed ID: 18337019
[TBL] [Abstract][Full Text] [Related]
16. Single nucleotide polymorphism-based genome-wide chromosome copy change, loss of heterozygosity, and aneuploidy in Barrett's esophagus neoplastic progression.
Li X; Galipeau PC; Sanchez CA; Blount PL; Maley CC; Arnaudo J; Peiffer DA; Pokholok D; Gunderson KL; Reid BJ
Cancer Prev Res (Phila); 2008 Nov; 1(6):413-23. PubMed ID: 19138988
[TBL] [Abstract][Full Text] [Related]
17. Multiple target sites of allelic imbalance on chromosome 17 in Barrett's oesophageal cancer.
Dunn J; Garde J; Dolan K; Gosney JR; Sutton R; Meltzer SJ; Field JK
Oncogene; 1999 Jan; 18(4):987-93. PubMed ID: 10023674
[TBL] [Abstract][Full Text] [Related]
18. Genetic mechanisms of TP53 loss of heterozygosity in Barrett's esophagus: implications for biomarker validation.
Wongsurawat VJ; Finley JC; Galipeau PC; Sanchez CA; Maley CC; Li X; Blount PL; Odze RD; Rabinovitch PS; Reid BJ
Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):509-16. PubMed ID: 16537709
[TBL] [Abstract][Full Text] [Related]
19. Mutation analysis of the p53, APC, and p16 genes in the Barrett's oesophagus, dysplasia, and adenocarcinoma.
González MV; Artímez ML; Rodrigo L; López-Larrea C; Menéndez MJ; Alvarez V; Pérez R; Fresno MF; Pérez MJ; Sampedro A; Coto E
J Clin Pathol; 1997 Mar; 50(3):212-7. PubMed ID: 9155671
[TBL] [Abstract][Full Text] [Related]
20. p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas.
Wong DJ; Barrett MT; Stöger R; Emond MJ; Reid BJ
Cancer Res; 1997 Jul; 57(13):2619-22. PubMed ID: 9205067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
